164 related articles for article (PubMed ID: 37823394)
21. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
22. Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS.
Barnidge DR; Tschumper RC; Theis JD; Snyder MR; Jelinek DF; Katzmann JA; Dispenzieri A; Murray DL
J Proteome Res; 2014 Apr; 13(4):1905-10. PubMed ID: 24552626
[TBL] [Abstract][Full Text] [Related]
23. [Simultaneous determination of three allergic proteins in rice and products by high performance liquid chromatography-tandem mass spectrometry combined with stable isotope-labeled peptides].
Yang H; Cao Z; Ma Y; Chen M
Se Pu; 2021 Dec; 39(12):1314-1323. PubMed ID: 34812003
[TBL] [Abstract][Full Text] [Related]
24. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
25. LC-MS/MS-based quantification of efflux transporter proteins at the BBB.
Gomez-Zepeda D; Taghi M; Smirnova M; Sergent P; Liu WQ; Chhuon C; Vidal M; Picard M; Thioulouse E; Broutin I; Guerrera IC; Scherrmann JM; Parmentier Y; Decleves X; Menet MC
J Pharm Biomed Anal; 2019 Feb; 164():496-508. PubMed ID: 30453156
[TBL] [Abstract][Full Text] [Related]
26. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
Anderson KC; Auclair D; Adam SJ; Agarwal A; Anderson M; Avet-Loiseau H; Bustoros M; Chapman J; Connors DE; Dash A; Di Bacco A; Du L; Facon T; Flores-Montero J; Gay F; Ghobrial IM; Gormley NJ; Gupta I; Higley H; Hillengass J; Kanapuru B; Kazandjian D; Kelloff GJ; Kirsch IR; Kremer B; Landgren O; Lightbody E; Lomas OC; Lonial S; Mateos MV; Montes de Oca R; Mukundan L; Munshi NC; O'Donnell EK; Orfao A; Paiva B; Patel R; Pugh TJ; Ramasamy K; Ray J; Roshal M; Ross JA; Sigman CC; Thoren KL; Trudel S; Ulaner G; Valente N; Weiss BM; Zamagni E; Kumar SK
Clin Cancer Res; 2021 Oct; 27(19):5195-5212. PubMed ID: 34321279
[TBL] [Abstract][Full Text] [Related]
27. Monitoring Both Extended and Tryptic Forms of Stable Isotope-Labeled Standard Peptides Provides an Internal Quality Control of Proteolytic Digestion in Targeted Mass Spectrometry-Based Assays.
Lundeen RA; Kennedy JJ; Murillo OD; Ivey RG; Zhao L; Schoenherr RM; Hoofnagle AN; Wang P; Whiteaker JR; Paulovich AG
Mol Cell Proteomics; 2023 Sep; 22(9):100621. PubMed ID: 37478973
[TBL] [Abstract][Full Text] [Related]
28. Mass Spectrometry Provides a Highly Sensitive Noninvasive Means of Sequencing and Tracking M-Protein in the Blood of Multiple Myeloma Patients.
McDonald Z; Taylor P; Liyasova M; Liu Q; Ma B
J Proteome Res; 2021 Aug; 20(8):4176-4185. PubMed ID: 34242034
[TBL] [Abstract][Full Text] [Related]
29. Multiple Myeloma Minimal Residual Disease.
Paiva B; García-Sanz R; San Miguel JF
Cancer Treat Res; 2016; 169():103-122. PubMed ID: 27696260
[TBL] [Abstract][Full Text] [Related]
30. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
[TBL] [Abstract][Full Text] [Related]
31. Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease.
Thoren KL
Semin Hematol; 2018 Jan; 55(1):41-43. PubMed ID: 29759153
[TBL] [Abstract][Full Text] [Related]
32. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Derman BA; Kansagra A; Zonder J; Stefka AT; Grinblatt DL; Anderson LD; Gurbuxani S; Narula S; Rayani S; Major A; Kin A; Jiang K; Karrison T; Jasielec J; Jakubowiak AJ
JAMA Oncol; 2022 Sep; 8(9):1278-1286. PubMed ID: 35862034
[TBL] [Abstract][Full Text] [Related]
33. Adaptation of a multiple myeloma minimal residual disease multicolor flow cytometry assay for real-world practice.
McMillan A; Tran TA; Galas-Filipowicz D; Camilleri M; Lecat C; Ainley L; Guo Y; Yong K; Sive J
Cytometry B Clin Cytom; 2023 Jul; 104(4):304-310. PubMed ID: 36370149
[TBL] [Abstract][Full Text] [Related]
34. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
[TBL] [Abstract][Full Text] [Related]
35. Measurable residual disease in multiple myeloma and in acute myeloid leukemia, an evolving topic.
Castelli G; Pelosi E; Testa U
Ann Ist Super Sanita; 2021; 57(4):300-313. PubMed ID: 35076420
[TBL] [Abstract][Full Text] [Related]
36. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
[TBL] [Abstract][Full Text] [Related]
37. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma.
Medina A; Jiménez C; Puig N; Sarasquete ME; Flores-Montero J; García-Álvarez M; Prieto-Conde I; Chillón C; Alcoceba M; González-Calle V; Gutiérrez NC; Jacobsen A; Vigil E; Hutt K; Huang Y; Orfao A; González M; Miller J; García-Sanz R
Arch Pathol Lab Med; 2022 Jul; 146(7):862-871. PubMed ID: 34619755
[TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
40. Mitigating analyte to stable isotope labelled internal standard cross-signal contribution in quantitative liquid chromatography-tandem mass spectrometry.
Radovanovic M; Jones G; Day RO; Galettis P; Norris RLG
J Mass Spectrom Adv Clin Lab; 2022 Apr; 24():57-64. PubMed ID: 35520954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]